18F-fluorodeoxyglucose positron emission tomography in kaposi sarcoma herpesvirus-associated multicentric castleman disease: Correlation with activity, severity, inflammatory and virologic parameters

Journal of Infectious Diseases

Volumn 212, Issue 8, 2015, Pages 1250-1260

  Polizzotto, Mark N ^a   Millo, Corina ^b   Uldrick, Thomas S ^a   Aleman, Karen ^a   Whatley, Millie ^b   Wyvill, Kathleen M ^a   O'mahony, Deirdre ^a   Marshall, Vickie ^c   Whitby, Denise ^c   Maass Moreno, Roberto ^b   Steinberg, Seth M ^a   Little, Richard F ^a   Yarchoan, Robert ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

^b NATIONAL INSTITUTES OF HEALTH   (United States)

^c FREDERICK NATIONAL LABORATORY FOR CANCER RESEARCH   (United States)

Author keywords

18F FDG positron emission tomography; Castleman disease; HIV; human herpesvirus 8 (HHV 8) Kaposi sarcoma herpesvirus (KSHV)

Indexed keywords

C REACTIVE PROTEIN; FLUORODEOXYGLUCOSE F 18; FLUORINE;

ANGIOFOLLICULAR LYMPH NODE HYPERPLASIA; ARTICLE; CLINICAL ARTICLE; DISEASE ACTIVITY; DISEASE SEVERITY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; IMAGE ANALYSIS; IMAGE PROCESSING; IMAGE QUALITY; KAPOSI SARCOMA; KAPOSI SARCOMA HERPESVIRUS ASSOCIATED MULTICENTRIC CASTLEMAN DISEASE; LIVER METABOLISM; LYMPHADENOPATHY; PET-CT SCANNER; PLEURA EFFUSION; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; PROSPECTIVE STUDY; PROTEIN BLOOD LEVEL; SALIVARY GLAND; SPLENOMEGALY; VIRUS LOAD; VIRUS REPLICATION; ADULT; COMPLICATION; FEMALE; HUMAN HERPESVIRUS 8; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LYMPH NODE; MALE; METABOLISM; MIDDLE AGED; PHYSIOLOGY; PROCEDURES; SCINTISCANNING; SPLEEN; VIROLOGY;

ADULT; C-REACTIVE PROTEIN; FEMALE; FLUORINE RADIOISOTOPES; FLUORODEOXYGLUCOSE F18; GIANT LYMPH NODE HYPERPLASIA; HERPESVIRUS 8, HUMAN; HIV INFECTIONS; HUMANS; LYMPH NODES; MALE; MIDDLE AGED; POSITRON-EMISSION TOMOGRAPHY; PROSPECTIVE STUDIES; SALIVARY GLANDS; SARCOMA, KAPOSI; SPLEEN;

EID: 84942934329     PISSN: 00221899     EISSN: 15376613     Source Type: Journal    
DOI: 10.1093/infdis/jiv204     Document Type: Article

References (51)

1. Oksenhendler E, Duarte M, Soulier J, et al. Multicentric Castlemans disease in HIV infection: a clinical and pathological study of 20 patients. AIDS. 1996; 10: 61
2. Bower M, Newsom-Davis T, Naresh K, et al. Clinical features and outcome in HIV-Associated multicentric Castlemans disease. J Clin Oncol. 2011; 29: 2481-6
3. Bower M. How I treat HIV-Associated multicentric Castlemans disease. Blood. 2010; 116: 4415-21
4. Uldrick TS, Polizzotto MN, Yarchoan R. Recent advances in Kaposi sarcoma herpesvirus-Associated multicentric Castleman disease. Curr Opin Oncol. 2012; 24: 495-505
5. Polizzotto MN, Uldrick TS, Hu D, Yarchoan R. Clinical manifestations of Kaposi sarcoma herpesvirus lytic activation: multicentric Castleman disease (KSHV-MCD) and the KSHV inflammatory cytokine syndrome. Front Microbiol. 2012; 3: 73
6. Chang Y, Cesarman E, Pessin MS, et al. Identification of herpesviruslike DNA sequences in AIDS-Associated Kaposis sarcoma. Science. 1994; 266: 1865-9
7. Soulier J, Grollet L, Oksenhendler E, et al. Kaposis sarcoma-Associated herpesvirus-like DNA sequences in multicentric Castlemans disease. Blood. 1995; 86: 1276-80
8. Dossier A, Meignin V, Fieschi C, Boutboul D, Oksenhendler E, Galicier L. Human herpesvirus 8-related Castleman disease in the absence of HIV infection. Clin Infect Dis. 2013; 56: 833-42
9. Polizzotto MN, Uldrick TS, Wang V, et al. Human and viral interleukin-6 and other cytokines in Kaposi sarcoma herpesvirus-Associated multicentric Castleman disease. Blood. 2013; 122: 4189-98
10. Aoki Y, Tosato G, Fonville TW, Pittaluga S. Serum viral interleukin-6 in AIDS-related multicentric Castleman disease. Thromb Haemost. 1995; 74: 449-53
11. Oksenhendler E, Carcelain G, Aoki Y, et al. High levels of human herpesvirus 8 viral load, human interleukin-6, interleukin-10, and C reactive protein correlate with exacerbation of multicentric Castleman disease in HIV-infected patients. Blood. 2000; 96: 2069
12. Uldrick TS, Polizzotto MN, Aleman K, et al. High-dose zidovudine plus valganciclovir for Kaposi sarcoma herpesvirus-Associated multicentric Castleman disease: a pilot study of virus-Activated cytotoxic therapy. Blood. 2011; 117: 6977-86
13. Gérard L, Bérezné A, Galicier L, et al. Prospective study of rituximab in chemotherapy-dependent human immunodeficiency virus associated multicentric Castlemans disease: ANRS 117 CastlemaB Trial. J Clin Oncol. 2007; 25: 3350-6
14. Hoffmann C, Schmid H, Müller M, et al. Improved outcome with rituximab in patients with HIV-Associated multicentric Castleman disease. Blood. 2011; 118: 3499-503
15. Cesarman E, Chang Y, Moore PS, Said JW, Knowles DM. Kaposis sarcoma-Associated herpesvirus-like DNA sequences in AIDS-related body-cavity-based lymphomas. N Engl J Med. 1995; 332: 1186-91
16. Naresh KN, Rice AJ, Bower M. Lymph nodes involved by multicentric Castleman disease among HIV-positive individuals are often involved by Kaposi sarcoma. Am J Surg Pathol. 2008; 32: 1006-12
17. Oksenhendler E, Boulanger E, Galicier L, et al. High incidence of Kaposi sarcoma-Associated herpesvirus-related non-Hodgkin lymphoma in patients with HIV infection and multicentric Castleman disease. Blood. 2002; 99: 2331
18. Seam P, Juweid ME, Cheson BD. The role of FDG-PET scans in patients with lymphoma. Blood. 2007; 110: 3507-16
19. Juweid ME, Stroobants S, Hoekstra OS, et al. Use of positron emission tomography for response assessment of lymphoma: consensus of the Imaging Subcommittee of International Harmonization Project in Lymphoma. J Clin Oncol. 2007; 25: 571-8
20. Mhlanga JC, Durand D, Tsai HL, et al. Differentiation of HIVassociated lymphoma from HIV-Associated reactive adenopathy using quantitative FDG PET. Eur J Nucl Med Mol Imaging. 2014; 41: 596-604
21. Okosun J, Warbey V, Shaw K, et al. Interim fluoro-2-deoxy-D-glucose-PET predicts response and progression-free survival in patients with Hodgkin lymphoma and HIV infection. AIDS. 2012; 26: 861-5
22. Elstrom R, Guan L, Baker G, et al. Utility of FDG-PET scanning in lymphoma by WHO classification. Blood. 2003; 101: 3875-6
23. Just PA, Fieschi C, Baillet G, Galicier L, Oksenhendler E, Moretti JL. 18F-fluorodeoxyglucose positron emission tomography/computed tomography in AIDS-related Burkitt lymphoma. AIDS Patient Care STDS. 2008; 22: 695-700
24. Dunleavy K, Little RF, Pittaluga S, et al. The role of tumor histogenesis, FDG-PET, and short-course EPOCH with dose-dense rituximab (SCEPOCH-RR) in HIV-Associated diffuse large B-cell lymphoma. Blood. 2010; 115: 3017-24
25. Brust D, Polis M, Davey R, et al. Fluorodeoxyglucose imaging in healthy subjects with HIV infection: impact of disease stage and therapy on pattern of nodal activation. AIDS. 2006; 20: 985-93
26. Martin C, Castaigne C, Tondeur M, Flamen P, De Wit S. Role and interpretation of fluorodeoxyglucose-positron emission tomography/.computed tomography in HIV-infected patients with fever of unknown origin: a prospective study. HIV Med. 2013; 14: 455-62
27. Sathekge M, Goethals I, Maes A, van de Wiele C. Positron emission tomography in patients suffering from HIV-1 infection. Eur J Nucl Med Mol Imaging. 2009; 36: 1176-84
28. Iyengar S, Chin B, Margolick JB, Sabundayo BP, Schwartz DH. Anatomical loci of HIV-Associated immune activation and association with viraemia. Lancet. 2003; 362: 945-50
29. Scharko AM, Perlman SB, Pyzalski RW, Graziano FM, Sosman J, Pauza CD. Whole-body positron emission tomography in patients with HIV-1 infection. Lancet. 2003; 362: 959-61
30. Love C, Tomas MB, Tronco GG, Palestro CJ. FDG PET of infection and inflammation. Radiographics. 2005; 25: 1357-68
31. Bleeker-Rovers CP, de Kleijn EM, Corstens FH, van der Meer JW, Oyen WJ. Clinical value of FDG PET in patients with fever of unknown origin and patients suspected of focal infection or inflammation. Eur J Nucl Med Mol Imaging. 2004; 31: 29-37
32. Mochizuki T, Tsukamoto E, Kuge Y, et al. FDG uptake and glucose transporter subtype expressions in experimental tumor and inflammation models. J Nucl Med. 2001; 42: 1551-5
33. Gamelli RL, Liu H, He LK, Hofmann CA. Augmentations of glucose uptake and glucose transporter-1 in macrophages following thermal injury and sepsis in mice. J Leukoc Biol. 1996; 59: 639-47
34. Kubota R, Yamada S, Kubota K, Ishiwata K, Tamahashi N, Ido T. Intratumoral distribution of fluorine-18-fluorodeoxyglucose in vivo: high accumulation in macrophages and granulation tissues studied by microautoradiography. J Nucl Med. 1992; 33: 1972-80
35. Hillier JC, Shaw P, Miller RF, et al. Imaging features of multicentric Castlemans disease in HIV infection. Clin Radiol. 2004; 59: 596-601
36. Barker R, Kazmi F, Stebbing J, et al. FDG-PET/CT imaging in the management of HIV-Associated multicentric Castlemans disease. Eur J Nucl Med Mol Imaging. 2009; 36: 648-52
37. Madan R, Chen JH, Trotman-Dickenson B, Jacobson F, Hunsaker A. The spectrum of Castlemans disease: mimics, radiologic pathologic correlation and role of imaging in patient management. Eur J Radiol. 2012; 81: 123-31
38. Lee ES, Paeng JC, Park CM, et al. Metabolic characteristics of Castleman disease on 18F-FDG PET in relation to clinical implication. Clin Nucl Med. 2013; 38: 339-42
39. Uldrick TS, Polizzotto MN, Aleman KA, et al. Rituximab plus liposomal doxorubicin in HIV-infected patients with KSHV-Associated multicentric Castleman disease. Blood. 2014; 124: 3544-52
40. National Cancer Institute. NCI common toxicity criteria for adverse Events v3.0. Bethesda, MD: US Department of Health and Human Services, 2006
41. Soret M, Bacharach SL, Buvat I. Partial-volume effect in PET tumor imaging. J Nucl Med. 2007; 48: 932-45
42. Venkataraman G, Uldrick TS, Aleman K, et al. Bone marrow findings in HIV-positive patients with Kaposi sarcoma herpesvirus-Associated multicentric Castleman disease. Am J Clin Pathol. 2013; 139: 651-61
43. Koelle DM, Huang ML, Chandran B, Vieira J, Piepkorn M, Corey L. Frequent detection of Kaposis sarcoma-Associated herpesvirus (human herpesvirus 8) DNA in saliva of human immunodeficiency virus-infected men: clinical and immunologic correlates. J Infect Dis. 1997; 176: 94-102
44. Bagni R, Whitby D. Kaposis sarcoma-Associated herpesvirus transmission and primary infection. Curr Opin HIV AIDS. 2009; 4: 22-6
45. Bower M, Veraitch O, Szydlo R, et al. Cytokine changes during rituximab therapy in HIV-Associated multicentric Castleman disease. Blood. 2009; 113: 4521-4
46. Sathekge M, Maes A, Kgomo M, Pottel H, Stolz A, Van De Wiele C. FDG uptake in lymph-nodes of HIV+ and tuberculosis patients: implications for cancer staging. J Nucl Med Mol Imaging. 2010; 54: 698-703
47. Stebbing J, Adams C, Sanitt A, et al. Plasma HHV8 DNA predicts relapse in individuals with HIV-Associated multicentric Castleman disease. Blood. 2011; 118: 271-5
48. Kainerstorfer JM, Polizzotto MN, Uldrick TS, et al. Evaluation of noninvasive multispectral imaging as a tool for measuring the effect of systemic therapy in Kaposi sarcoma. PLoS One. 2013; 8: e83887
49. Fu DX, Tanhehco YC, Chen J, et al. Virus-Associated tumor imaging by induction of viral gene expression. Clin Cancer Res. 2007; 13: 1453-8
50. Uldrick TS, Wang V, OMahony D, et al. An interleukin-6-related systemic inflammatory syndrome in patients co-infected with Kaposi sarcoma-Associated herpesvirus and HIV but without multicentric Castleman disease. Clin Infect Dis. 2010; 51: 350-8
51. Letang E, Lewis JJ, Bower M, et al. Immune reconstitution inflammatory syndrome associated with Kaposi sarcoma. AIDS. 2013; 27: 1603-13